SalioGen Therapeutics, a company that raised $135 million to develop new gene-editing technology, is facing layoffs and scaling back its plans. The company, founded in 2021, was focused on inserting full-length genes into patients, a task not easily achievable with older gene-editing methods like CRISPR. This move follows other high-profile gene-editing companies making similar cutbacks. The company declined to comment on the situation. This development highlights the challenges faced by emerging biotech companies in the gene-editing space, as they navigate the complexities of developing cutting-edge technologies while managing financial constraints.
Source link
SalioGen Therapeutics, a gene-editing biotech company, is hit by layoffs
